Quadrature Capital’s Legend Biotech LEGN Stock Holding History

Quadrature Capital’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-47,278	Closed	-$1.54M	–	1490
2025 Q3	$1.54M	Buy	+47,278	New	+$1.75M	0.02%	335

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Quadrature Capital's LEGN Position: Q4 2025 in Review

Quadrature Capital sold out of Legend Biotech (LEGN) in Q4 2025, closing a stake of 47,278 shares — an estimated $1.54M sold.

Quadrature Capital first reported a position in LEGN in Q3 2025 and held it in 1 quarter. The position peaked at $1.54M in Q3 2025. 198 funds tracked by Wall St. Rank hold LEGN as of Q4 2025.

Quadrature Capital reported no remaining Legend Biotech position as of Q4 2025 after selling out during the quarter.
Quadrature Capital sold 47,278 Legend Biotech shares in Q4 2025, an estimated $1.54M.
Quadrature Capital first reported a position in Legend Biotech in Q3 2025 and held it in 1 quarter.
Quadrature Capital's Legend Biotech position peaked at $1.54M in Q3 2025.
198 funds tracked by Wall St. Rank held Legend Biotech as of Q4 2025.

Based on Quadrature Capital's 13F filing for Q4 2025, filed 17 Feb 2026.